Disclosed is the use of activated T cells and a PD-1 antagonist in the manufacture of a medicament for inducing an immune response to a tumor antigen of interest in a mammalian subject having a tumor for treating said tumor, wherein the T cells specifically recognize the tumor antigen of interest and wherein the tumor is a lymphoproliferative cancer. Also disclosed is the use of a Programmed Death (PD-1) antagonist and a tumor antigen or a nucleic acid encoding the tumor antigen in the manufacture of a medicament for treating a mammalian subject having lymphoproliferative cancer.
